Change of Adviser and Broker

RNS Number : 3518U
Oxford Biomedica PLC
14 October 2010



Change of Adviser and Broker


Oxford, UK - 14 October 2010: Oxford BioMedica ("the Company") (LSE: OXB), a leading gene therapy company, today announces that it has appointed Singer Capital Markets Limited as its corporate broker and financial adviser with immediate effect.




For further information, please contact:

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Andrew Wood, Chief Financial Officer


Tel: +44 (0)1865 783 000


Singer Capital Markets Limited:

Shaun Dobson

Claes Spång


Tel: +44 (0)20 3205 7500




Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at

This information is provided by RNS
The company news service from the London Stock Exchange